5-amino levulinic acid inhibits SARS-CoV-2 infection in vitro
Y. Sakurai, M. M. N. Tun, Y. Kurosaki, T. Sakura, D. K. Inaoka, K. Fujine, K. Kita, K. Morita, J. Yasuda
Abstract
The current COVID-19 pandemic requires urgent development of effective therapeutics. 5-amino levulinic acid (5-ALA) is a naturally synthesized amino acid and has been used for multiple purposes including as an anticancer therapy and as a dietary supplement due to its high bioavailability. In this study, we demonstrated that 5-ALA treatment potently inhibited infection of SARS-CoV-2, a causative agent of COVID-19. The antiviral effects could be detected in both human and non-human cells, without significant cytotoxicity. Therefore, 5-ALA is a candidate as an oral antiviral drug for COVID-19.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Nelfinavir inhibits replication of severe acute respiratory syndrome coronavirus 2 in vitro.
N. Yamamoto, S. Matsuyama, … N. Yamamoto·bioRxiv·Apr 6, 2020
- A natural broad-spectrum inhibitor of enveloped virus entry, effective against SARS-CoV-2 and Influenza A Virus in preclinical animal models.
R. Narayan, M. Sharma, … S. Tripathi·bioRxiv·Feb 16, 2022
- Potential antiviral options against SARS-CoV-2 infection
A. Ianevski, R. Yao, … D. E. Kainov·bioRxiv·May 12, 2020
- A novel antiviral formulation inhibits SARS-CoV-2 infection of human bronchial epithelium
K. Purves, R. Haverty, … N. F. Fletcher·bioRxiv·Oct 5, 2022
- Prophylactic and Therapeutic Inhibition of In Vitro SARS-CoV-2 Replication by Oleandrin
K. S. Plante, J. A. Plante, … S. C. Weaver·bioRxiv·Jul 15, 2020
- Glycyrrhizin effectively neutralizes SARS-CoV-2 in vitro by inhibiting the viral main protease
Lukas van de Sand, Maren Bormann, … Adalbert Krawczyk·VirusesPeer-reviewed·Apr 2, 2021